Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04019067
Other study ID # MCE-melena-2019
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date December 1, 2020
Est. completion date September 1, 2022

Study information

Verified date September 2020
Source Changhai Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

MCE first algorithm is not inferior to standard of care algorithm in terms of further bleeding in hemodynamically stable patients with acute overt and non-hematochezia GI bleeding.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date September 1, 2022
Est. primary completion date September 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age = 18 years

- Presenting to the outpatient department or emergency department with melena (without hematemesis) within the previous 48 hours

- Hemodynamically stable (blood pressure > 100/60 mmHg and heart rate < 100 bpm) at presentation

- No endoscopy performed after the new onset of melena

Exclusion Criteria:

- Presenting with hematochezia and/or hematemesis within the previous 48 hours of presentation

- Hemodynamically stable after initial volume resuscitation

- Drop of hemoglobin level = 2 g/dL/day, and/or need of transfusion = 2 units of packed red blood cells per day

- Contraindications of CE (e.g. dysphagia, Zenker's diverticulum, esophageal stricture, known or suspected gastric or small bowel obstruction or perforation, gastroparesis, history of upper gastrointestinal surgery or abdominal surgery altering gastrointestinal anatomy, or post-abdominal radiation, etc.)

- Presence of internal cardiac defibrillator (ICD), pacemaker and/or other implanted electronic devices (cochlea, drug infusion pump, nerve stimulator, etc.) or magnetic metal foreign bodies; possibility of requiring an MRI examination prior to capsule excretion

- Patients who cannot undergo surgery in the event of capsule retention

- Pregnant and/or lactating women

- Patients with altered mental status (such as hepatic encephalopathy)

- Patients moribund from terminal malignant diseases or other end-stage illnesses with a limited life expectancy

- Unable to consent

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
MCE first
Patients randomized to the "MCE first group" will have a MCE deployed as soon as possible once confirmed to fast for at least 8 hours.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Changhai Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary The rate of bleeding lesions detection. Detection rate of bleeding lesions is defined as proportion of patients in whom a potential bleeding lesion is identified. Visualization of gross blood (fresh/coffee grounds) without any lesion will not be considered as a positive diagnosis. The panel will provide a diagnosis based upon the lesion presenting the highest potential for bleeding if there are many lesions detected. 1 month
Secondary The time of the bleeding lesions detected from admission 1 month
Secondary The number of procedures patients underwent for detection of the bleeding lesions 1 month
Secondary The number of colonoscopy needed 1 month
Secondary Rate of therapeutic intervention required of all patients Therapeutic interventions include therapeutic endoscopy, radiologic intervention or surgery. 1 month
Secondary The length of hospital stay 1 month
Secondary The cumulative direct cost of hospitalization 1 month
Secondary Time to therapeutic intervention from presentation 1 month
Secondary The rate of recurrent bleeding within 30 days of discharge Further bleeding is defined as overt (hematemesis, melena or hematochezia) or occult (anemia or fecal occult blood positive) bleeding requiring subsequent hospitalization or transfusion, and/or signs of hypovolemic shock (systolic blood pressure of <100 mmHg and pulse rate >100 per min) or a drop-in hemoglobin level of >2g/dL per 24hours. 1 month
Secondary The all-cause mortality within 30 days of discharge 1 month
Secondary Transfusion rate 1 month
See also
  Status Clinical Trial Phase
Completed NCT00389935 - Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding Phase 2
Completed NCT00534677 - The Safety & Efficacy of Terlipressin vs Octreotide for the Control of Variceal Bleed Phase 4
Active, not recruiting NCT01863303 - Epidemiological Study of Colorectal Cancer in WuHan N/A
Completed NCT03028064 - Point of Care Testing of Platelet Function in Patients With Acute Upper Gastrointestinal Bleeding
Completed NCT03955055 - Study of Early Endocapsule (EC) in Clinical Decision Unit Versus Standard of Care Work-up for GI Bleeding N/A
Completed NCT02442830 - Comparing Early Capsule Deployment to Current Standard of Care for Management of Gastrointestinal Bleeding N/A
Not yet recruiting NCT01371591 - Capsule Endoscopy for Hemorrhage in the Emergency Room N/A